

GLAXOSMITHKLINE PLC  
Form 6-K  
February 25, 2010

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February, 2010

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

## Notification of Transactions of Directors and Persons Discharging Managerial Responsibility

### 2007 GlaxoSmithKline Performance Share Plan award Sale of shares to meet tax liability

I give below details of changes in the interests of:

.

Directors and Persons Discharging Managerial Responsibility in the Ordinary shares of GlaxoSmithKline plc in respect of the under mentioned persons arising from the sale of Ordinary shares at a price of £12.08 per Ordinary Share on 24 February 2010 to meet their tax liabilities following the vesting of a Performance Share Plan (PSP) award:

#### No. of Ordinary shares sold to meet tax liabilities following the vesting of a PSP award

|                 |        |
|-----------------|--------|
| Mr A P Witty*   | 13,851 |
| Mr J S Heslop*  | 17,109 |
| Mr S M Bicknell | 724    |
| Mr J M Clarke   | 12,547 |
| Mr M Dunoyer    | 4,726  |
| Mr E J Gray     | 962    |
| Mr D Learmouth  | 3,463  |
| Mr D S Redfern  | 962    |
| Ms C Thomas     | 724    |

\* Denotes an Executive Director

.

Persons Discharging Managerial Responsibility in the American Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the under mentioned persons arising from the withholding of shares at a price of \$37.42 per ADS on 24 February 2010 to meet their tax liabilities following the vesting of a Performance Share Plan award:

#### No. of ADSs withheld to meet tax liabilities following the vesting of a PSP award

|                |        |
|----------------|--------|
| Dr M M Slaoui* | 11,262 |
| Mr W C Louv    | 3,228  |
| Mr D Phelan    | 5,124  |
| Mr D Pulman    | 3,228  |

\* Denotes an Executive Director

The Company, Directors, Persons Discharging Managerial Responsibility were advised of these transactions on 24 February 2010.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Deputy Company Secretary

25 February 2010

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 25, 2010

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc